Japan becomes first country to approve regeneron antibody cocktail (casirivimab and imdevimab) for the treatment of mild to moderate covid-19

Tarrytown, n.y., july 20, 2021 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that japan's ministry of health, labour and welfare (mhlw) has approved regeneron's casirivimab and imdevimab antibody cocktail to treat patients with mild to moderate covid-19.

REGN Ratings Summary

REGN Quant Ranking